Poland· PL-100463484
Cibinqo
A abrocitinib product containing abrocitinibum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Abrocitinib is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH08 (abrocitinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Abrocitinib · ATC D11AH08
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abrocitinib costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.26 in France to $122.11 in Switzerland — a ×472 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Abrocitinib · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$122.11
- FR France$0.26
The record
At a glance
URPL (Poland)- Active substance
- Abrocitinibum
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Poland (PL)
- ATC code
- D11AH08
- ATC class
- Abrocitinib
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05415062384572
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Abrocitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCibinqoPfizer Laboratories Div Pfizer Inc
- CzechiaCIBINQOPfizer Europe MA EEIG, Bruxelles
- FinlandCibinqoPfizer Europe MA EEIG
- FranceCIBINQO 200 mg, comprimé pelliculéPFIZER EUROPE MA EEIG (BELGIQUE)
- BelgiumCibinqo 200 mgPfizer Europe MA
- IcelandCibinqoPfizer Europe MA EEIG*
- NetherlandsCibinqo 200 mg, filmomhulde tablettenPfizer Europe MA EEIG
- NorwayCibinqoPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cibinqo
- Liechtenstein · Cibinqo
- Norway · Cibinqo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c90aa8c6-4a3f-452e-adf0-9f3c7d1b920e GET /v1/drugs/c90aa8c6-4a3f-452e-adf0-9f3c7d1b920e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "200 mg",
"packaging": "05415062384572 ¦ Rpz ¦ EU/1/21/1593/014 ¦ 143468\n28 tabl.\nRpz ¦ EU/1/21/1593/013 ¦ 143469\n14 tabl. w blistrze\nRpz ¦ EU/1/21/1593/015 ¦ 143470\n91 tabl.\nRpz ¦ EU/1/21/1593/011 ¦ 143471\n14 tabl. w butelce\nRpz ¦ EU/1/21/1593/012 ¦ 143472\n30 tabl.",
"substance": "Abrocitinibum 200 mg",
"common_name": "Abrocitinibum",
"pl_product_id": "100463484",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about abrocitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.